Business Wire

Bermuda Represented at International Private Client Forum in Lake Como, Italy

22.11.2022 16:37:00 EET | Business Wire | Press release

Share

From November 17-19, a delegation from Bermuda travelled to Lake Como, Italy to promote Bermuda as a premier domicile for high-net-worth services to private client lawyers from all over the world

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005517/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bermuda representatives (from left) Alec Anderson, Quadrant Advisors; Lorinda Gazzard, Butterfield; Keith Robinson, Carey Olsen; Randall Krebs, Harbour International Trust Company; Scott Pearman, Conyers; Craig W. MacIntyre, Conyers; David Hart, BDA; Andrea Jackson, BDA; Michael Neff, Butterfield; Kevin Dallas, Butterfield; Nir Sadeh, Butterfield; Jeffrey P. Elkinson, Conyers; Gina Pereira, Meritus Trust. (Photo: Business Wire)

Representing the BDA was CEO David Hart and independent board member, Andrea Jackson, while senior representatives from Butterfield, Carey Olsen, Conyers, Harbour International, Meritus Trust, and Quadrant Advisors were also in attendance.

David Hart said, “The BDA’s main purpose here at the International Private Client Forum, which is held in association with Butterfield, is to share the message of Bermuda's safety and stability as a blue-chip jurisdiction for attracting and welcoming foreign direct investment. There is a larger Bermuda delegation here beyond the BDA, including leading professionals in our legal, banking and trust communities, all of whom have substantial experience in advising high net worth individuals and families and are at the forefront of the private wealth industry.”

Michael Neff, Butterfield’s Managing Director of Bermuda and International Wealth, welcomed delegates to the three-day forum of panel discussions, roundtables and workshops. Carey Olsen Bermuda partner and head of the Bermuda disputes team, Keith Robinson, spoke on a panel session entitled 'Drafting Carefully: Planning Lessons Learned from Recent Cases' and Conyers director Scott Pearman joined a roundtable discussion entitled ‘Criminal Enforcement: Our Shifting Role’.

Bermuda’s attendance at what is referred to as the world’s preeminent gathering of private client lawyers builds on three major in-person high-net-worth services events that returned to Bermuda this summer, the first since 2019.

Along with Butterfield, the BDA co-sponsored a ‘Private Client Exchange Bermuda 2022’ event in June 28-29. This sold-out event brought about 50 of the world’s top lawyers to the St Regis Bermuda Resort.

As part of our commitment to Bermuda’s high net worth services industry, the BDA also sponsored two other in-person international trust and private investors events in June and July. These events not only brought global trust and legal leaders to the Island to discuss important hot topics and best practices but the immediate economic impact of the first two, including lodging, transportation, food and beverage, retail and recreation, was estimated at over half million dollars, and supported around 240 jobs.

If you would like to learn more about Bermuda’s high-net-worth services sector, contact Korrin Lightbourne, Senior Business Development Coordinator at info@bda.bm or +1 441 292 0632.

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stuart Roberts, Director of Communications & PR
stuart@bda.bm | +1 441 292 7774

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye